Ultravate is owned by Sun Pharm Industries.
Ultravate contains Halobetasol Propionate.
Ultravate has a total of 1 drug patent out of which 0 drug patents have expired.
Ultravate was authorised for market use on 06 November, 2015.
Ultravate is available in lotion;topical dosage forms.
Ultravate can be used as use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis.
The generics of Ultravate are possible to be released after 19 June, 2033.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8962028||SUN PHARM INDUSTRIES||Topical steroid composition and method|| |
(10 years from now)
|New Patient Population (NPP)||Aug 31, 2023|
Market Authorisation Date: 06 November, 2015
Treatment: Use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic